About Us
···Services
- Regulatory Affairs
- Clinical Operations
- Data Management
- Biostatistics
- Medical Services
- Pharmacovigilance
- Quality Assurance
- Biotech Consultancy
- Patient Recruitment
We assemble a team of senior medical experts with specific knowledge in all key therapeutic areas.
Our senior medical experts have monitored many trials across Europe covering all key therapeutic areas. We have gained a depth of knowledge which has allowed us to apply new insights and innovative science to clinical trials.
Selected examples:
| Sponsor | Phase | Description | Patients | Sites | Countries |
|---|---|---|---|---|---|
| US Biotech | III | Hormone therapy in post chemo-therapy castration-resistant prostate cancer | 500 | 58 | 10 |
| US Biotech | III | Hormone therapy in pre chemo-therapy castration-resistant prostate cancer | 350 | 75 | 9 |
| US Biotech | III | Pigmented villonodular sinovitis or giant cell tumor of tendon sheath | 120 | 18 | 8 |
| US Biotech | II | Chemotherapy as second line in Small Cell Lung Cancer | 85 | 18 | 2 |
| German Biotech | I | Monoclonal antibody in platinum-resistant ovarian cancer | 40 | 8 | 3 |
| US Biotech | II | Anti Her treatment in patients with Her2-3 mutation and solid cancer of EGFR amplification in brain tumors | 70 | 16 | 7 |
| US Biotech | II | Anti-Parp in breast cancer in third or further line | 60 | 26 | 7 | US Biotech | III | Anti-Parp in breast cancer in patients that have progressed to no more than 3 prior chemotherapy lines | 200 | 68 | 11 | US Biotech | I | Targeted therapy plus chemotherapy in Multiple Myeloma | 24 | 8 | 3 | US Biotech | II | Targeted therapy in relapsed/refractory Myeloma | 12 | 8 | 2 | US Biotech | II | Targeted therapy in combination in patients with Chronic Lymphocytic Leukemia | 20 | 80 | 2 | US Biotech | II | Mechanically ventilated and tube-fed patients with enteral feeding intolerance treated with prokinetic compound | 20 | 20 | 2 | US Biotech | II | Targeted therapy in primary immunodeficiency | 15 | 40 | 7 | US Biotech | III | Oncolytic virus in head & neck cancer | 250 | 70 | 11 | US Biotech | III | Antiandrogen therapy in pre chemotherapy castration-resistant prostate cancer | 75 | 50 | 6 | US Biotech | III | Targeted therapy in metastatic NSCLC | 266 | 21 | 128 | US Biotech | II | Anti/Her2 target therapy or placebo in combination with trastuzumab and Capecitabine in previously treated Her2 positive breast cancer patients | 480 | 150 | 17 | US Biotech | II | PARP inhibitor in castration/resistant prostate cancer patients with Holomogous Recombination deficiency | 157 | 125 | 13 | US Biotech | III | PARP inhibitor vs physician’s choice in castration resistant prostate cancer | 400 | 125 | 13 | US Biotech | II | Immunotherapy with CD-40 agonist in immune-naïve melanoma patients | 46 | 8 | 3 |
